Email: ielsg@ior.usi.ch /
Phone: + 41 58 666 73 04/05/06
LATEST NEWS
- Register now! – IELSG Annual Meeting 2023
The next Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG) will be held on March 17-18, 2023 in Stresa (Italy) at Hotel La Palma.
Participants receive all information individually soon.
Registrations are open.
- IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
Reference IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. Link Author(s) Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domènech ED, Tucci A, Mannina D, Merli M, Salar A, Visco C, Esposito F, Bonomini L, Zucca E, Ferreri AJM, Raderer M. Study IELSG40
ONGOING STUDIES
- IELSG50IELSG50 Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy Participants required: 30 […]
- IELSG49IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
- IELSG44IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
LATEST NEWSLETTER
- Newsletter Number 53
Click here to open the pdf file – Click here to read the newsletter in HTML
- Newsletter Number 52
PUBLICATIONS
- IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphomaReference IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. Link Author(s) Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domènech ED, Tucci A, Mannina D, Merli M, Salar […]
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialReference Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Link Author(s) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, […]